Okyo Pharma Ltd (OKYO)
$0.99
Live
Performance
- $0.99$1.04$0.99
0.0%
Downside
Day's Volatility :4.81%
Upside
4.81%
- $0.81$2.12$0.99
18.43%
Downside
52 Weeks Volatility :61.91%
Upside
53.3%
Returns
| Period | Okyo Pharma Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -39.29% | 0.0% |
6 Months | -25.0% | 0.0% |
1 Year | -37.42% | 0.0% |
3 Years | -71.82% | -23.0% |
Highlights
Market Capitalization | 34.2M |
Book Value | -$0.18 |
Earnings Per Share (EPS) | -0.57 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -291.87% |
Return On Equity TTM | -2968.51% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -3.6M |
EBITDA | -15.7M |
Diluted Eps TTM | -0.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Technicals Summary
Sell
Neutral
Buy
Okyo Pharma Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Okyo Pharma Ltd | 0.99% | -25.0% | -37.42% | -71.82% | -71.82% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Okyo Pharma Ltd | NA | NA | NA | 0.0 | -29.69 | -2.92 | NA | -0.18 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Okyo Pharma Ltd | Buy | $34.2M | -71.82% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Okyo Pharma Ltd
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 118.7%
Institutional Holdings
Barclays PLC
2.84%HPM Partners LLC
0.04%Geode Capital Management, LLC
0.04%HSBC Holdings PLC
0.04%Susquehanna International Group, LLP
0.03%UBS Group AG
0.01%
Company Information
Organization | Okyo Pharma Ltd |
Employees | 8 |
CEO | Dr. Gary S. Jacob Ph.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.99
-2.94%
Invesco Bulletshares 2025 Hi
$0.99
-2.94%
Schwab International Dividend Equity Etf
$0.99
-2.94%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.99
-2.94%
Lightpath Technologies Inc
$0.99
-2.94%
Vaneck Vectors Global Alternative Energy Etf
$0.99
-2.94%
First Trust Flexible Municipal High Income Etf
$0.99
-2.94%
Drx Dly Reg Bank Bull 3x
$0.99
-2.94%
Graniteshares 2x Long Pltr Daily Etf
$0.99
-2.94%